Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have multiple myeloma and need systemic (whole-body) treatment, currently in their third line of treatment (note: first-line and second-line recruitment is closed)
- People who are 18 years of age or older
- People who are willing and able to sign a written consent form before joining
- For those taking part in the patient-reported outcomes (PRO) section of the trial: consent and a baseline questionnaire must be completed before starting treatment, but no more than eight weeks before treatment begins
- For those not taking part in the PRO section: consent must be signed no later than four weeks after starting treatment, and no more than eight weeks before treatment begins
- People taking part in the PRO section must have a sufficient level of German language skills to complete the questionnaires
Who may not be able to join:
- People with myeloma who are not receiving any systemic (whole-body) treatment
- People who are already enrolled in another study that does not allow participation in additional studies at the same time
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hermann Einsele, Prof MD, Wuerzburg University Hospital
Phone: +49 761 15242-0
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Course of treatment (treatment reality)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.